Mark G Lebwohl
Overview
Explore the profile of Mark G Lebwohl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
175
Citations
3736
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gordon K, Augustin M, Barker J, Tada Y, Lebwohl M, Tang M, et al.
J Am Acad Dermatol
. 2025 Mar;
PMID: 40057892
Background: Generalized pustular psoriasis (GPP) is a chronic inflammatory disease with an unpredictable disease course. Long-term treatment goals include sustained resolution of skin symptoms, prevention of new flares, and improvement...
2.
Hollield C, Amara S, M Lewin J, Lebwohl M
J Drugs Dermatol
. 2025 Mar;
24(3):329-331.
PMID: 40043261
Neoadjuvant Hedgehog Pathway Inhibitor (HPI) therapy, utilizing sonidegib and vismodegib, has shown great potential in managing locally advanced basal cell carcinoma (laBCC). While effective, the tolerability of HPI therapy may...
3.
Lebwohl M, Koo J, Jaworski J, Trefler J, Daniluk S, Dudek A, et al.
Adv Ther
. 2025 Feb;
42(3):1582-1599.
PMID: 39932677
Introduction: This study aimed to demonstrate the interchangeability of biosimilar CT-P17 and European Union reference adalimumab (EU-adalimumab) in a repeated-switch scenario. Methods: In this ongoing, randomized, double-blind, active-controlled, phase 3...
4.
Elewski B, Lebwohl M
J Psoriasis Psoriatic Arthritis
. 2025 Feb;
:24755303251318976.
PMID: 39906749
Generalized pustular psoriasis (GPP) is a rare, chronic inflammatory skin disease characterized by persistent symptoms and sudden flares of painful sterile pustules, sometimes accompanied by systemic inflammation. Patients with GPP...
5.
6.
Lebwohl M, Koo J, Armstrong A, Strober B, Yoon S, Rawnsley N, et al.
Dermatol Ther (Heidelb)
. 2024 Nov;
15(1):213-222.
PMID: 39589679
Introduction: Brodalumab is a human interleukin-17 receptor A antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have...
7.
Elewski B, Lebwohl M
Clin Cosmet Investig Dermatol
. 2024 Nov;
17:2487-2493.
PMID: 39530063
Generalized pustular psoriasis (GPP) is a rare, chronic, inflammatory skin disease characterized by persistent symptoms and sudden flares of painful, sterile pustules, and may be accompanied by systemic inflammation. Ongoing...
8.
Wei N, Chi S, Lebwohl M
J Psoriasis Psoriatic Arthritis
. 2024 Sep;
7(2):55-59.
PMID: 39296827
: Interleukin (IL)-23 antagonists have shown great efficacy with minimal side effect profile in clinical trial data for the treatment of moderate to severe plaque psoriasis. As of yet, there...
9.
Lebwohl M, Medeiros R, Mackey R, Valdecantos W, Brodovicz K, Lertratanakul A, et al.
J Psoriasis Psoriatic Arthritis
. 2024 Sep;
8(2):56-65.
PMID: 39296672
Background: Palmoplantar pustulosis (PPP) is a rare skin disease characterized by episodes of neutrophilic pustules on the palms of the hands and soles of the feet. Current treatments for PPP...
10.
Mease P, Blauvelt A, Sima A, Beaty S, Low R, Gomez B, et al.
Dermatol Ther (Heidelb)
. 2024 Sep;
14(10):2805-2825.
PMID: 39283415
Introduction: Patients with psoriasis (PSO) and psoriatic arthritis (PsA) may frequently switch biologic therapies over the course of treatment because of symptom variability and individual responses. Real-world studies analyzing patient...